An Observational Study of Patients With Coronavirus Disease 2019

Target PharmaSolutions, Inc.199 enrolled

Overview

This is an observational study of patients with COVID-19 designed to specifically address important clinical questions that remain incompletely answered for coronavirus disease 2019.

Data from up to 5,000 adult patients in the US will be captured from eligible patients enrolled following admission to the hospital. Participants will have de-identified medical records collected from hospital admission to discharge, including but not limited to critical care monitoring, details on mechanical ventilation, laboratory data, imaging reports, medications, and all procedures. Diagnosis and patient management will follow each hospital's standard of care and no specific treatments, procedures or laboratory tests will be dictated by enrollment in TARGET-COVID-19.

Study Type

OBSERVATIONAL

Enrollment

199

Conditions

COVID-19 Coronavirus

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (age ≥18 years) who are or have been hospitalized and diagnosed with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection. * SARS-CoV-2 confirmed diagnosis (e.g. polymerase chain reaction \[PCR\] or other clinically utilized test). Exclusion Criteria: N/A

Locations (1)

University of Washington

Seattle, Washington, United States

Outcomes

Primary Outcomes

Natural history of COVID-19: Characteristics of COVID-19

Time frame: 12 months

Natural history of COVID-19: Participant demographics

Time frame: 12 months

Natural history of COVID-19: Treatment use

Time frame: 12 months

Time point of clinical response

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.